Ubenimex Completed Phase 2 Trials for Pulmonary Arterial Hypertension (PAH) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02664558A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)